ClinicalTrials.gg
CompletedNCT02581631CheckMate 436Updated Mar 7, 2023Results posted

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

A Phase 1/2 interventional study of Nivolumab and Brentuximab Vedotin in Non-Hodgkin's Disease, sponsored by Bristol-Myers Squibb. Completed at 27 sites in 6 countries. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2023-03-07.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
145
Allocation
Not applicable
Ages
15 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether Nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-Hodgkin's lymphomas with CD30 expression that have not responded to treatment or have come back. The subtypes we are studying are Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Primary Mediastinal Large B-Cell Lymphoma (PMBL) and Mediastinal Gray Zone Lymphoma (MGZL).

02

Conditions studied

  • Non-Hodgkin's Disease
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • diffuse large B cell lymphoma (DLBCL), relapsed/refractory peripheral T cell lymphoma (PTCL) (all subtypes excluding anaplastic large cell lymphoma), relapsed/refractory Cutaneous T cell lymphoma (CTCL) mycosis fungoides/sezary syndrome (MF/SS), relapsed/refractory primary mediastinal B lymphoma (PMBL), and relapsed/refractory mediastinal gray zone lymphoma (MGZL)
  • Expression of CD30
  • Subjects must be 18 years or older (≥ 15 years for PMBL)

Exclusion criteria

Exclusion Criteria:

  • Known central nervous system (CNS) lymphomas; Active cerebral/meningeal disease related to the underlying
  • Active, known, or suspected disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    Nivolumab+Brentuximab Vedotin

    Nivolumab+Brentuximab Vedotin dose as specified

    Biological: Nivolumab · Drug: Brentuximab Vedotin

Interventions

06

What researchers measure

Primary outcomes

  1. Safety Analysis - Number of Participants With Dose Limiting Toxicities (DLT) in the DLT Evaluation Phase

    DLTs are defined as any study drug-related toxicity (brentuximab vedotin or nivolumab) that requires either a dose reduction or delay of more than 7 days of either study drug in Cycle 2 or delays the Cycle 3 Day 1 administration of combined treatment by more than 7 days.

    Time frame: From first dose of treatment to 6 weeks after first dose

  2. Safety Analysis - Number of Participant Deaths

    Number of participant Deaths

    Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months

  3. Safety Analysis - Number of Participants With Adverse Advents

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.

    Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months

  4. Safety Analysis - Number of Participants With Serious Adverse Events

    A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * results in death * is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * requires inpatient hospitalization or causes prolongation of existing hospitalization. * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event

    Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months

  5. Safety Analysis - Number of Participants With Adverse Events Leading to Discontinuation

    Number of participants with adverse events leading to discontinuation

    Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months

  6. Safety Analysis - Number of Participants With Adverse Events Leading to Dose Delay or Reduction

    Number of participants with adverse events leading to dose delay or reduction

    Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months

  7. Safety Analysis - Number of Participants With Drug Related Adverse Events

    Number of participants with Drug Related Adverse Events

    Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months

  8. Safety Analysis - Percentage of Participants With Thyroid Test Abnormalities

    Percentage of participants with specific thyroid test abnormalities

    Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months

  9. Safety Analysis - Percentage of Participants With Liver Test Abnormalities

    Percentage of participants with specific Liver test abnormalities

    Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months

  10. Objective Response Rate (ORR)

    The percentage of participants with a best overall response (BOR) of CR or PR. DLBCL, PTCL, PMBL \& MGZL complete and partial response are outlined in the Lugano Classification 2014 and Lymphoma Response to Immunomodulatory therapy Criteria. CTCL complete and partial response are defined in The consensus Global Response Score assessment.

    Time frame: CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months

Secondary outcomes

  1. Duration of Response (DOR)

    DOR will be calculated from the date of initial documentation of a response (CR, or PR) to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death due to any cause, whichever occurs first. DLBCL, PTCL, PMBL \& MGZL complete and partial response are outlined in the Lugano Classification 2014 and Lymphoma Response to Immunomodulatory therapy Criteria. CTCL complete and partial response are defined in The consensus Global Response Score assessment.

    Time frame: From the first patient first visit to 8 months after the last patient first visit (up to 48 months)

  2. Complete Response Rate (CRR)

    The CRR is defined as the percentage of participants with a BOR (Best overall response) of CR divided by the number of treated participants. DLBCL, PTCL, PMBL \& MGZL (CR) 1.Complete disappearance of all detectable clinical evidence of disease. 2.Bone marrow: No evidence of FDG- avid disease in marrow. CTCL (CR) 1. 100% clearance of skin lesions. 2. all lymph nodes ≤1.5 cm, N3 classification and ≤ 1.5 cm in their long axis and \> 1 cm in their short axis at baseline, must be ≤ 1 cm in their short axis or biopsy negative for lymphoma. 3. organs should not be enlarged on examination or imaging 4. absence of blood involvement

    Time frame: From first dose to the date of initial objectively documented progression or the date of subsequent therapy, whichever occurs first (up to 48 months)

  3. Duration of Complete Response

    The duration of CR will only be evaluated in participants with BOR of CR and is defined as the time from first documentation of CR to the date of relapse or death due to any cause, whichever occurs first. DLBCL, PTCL, PMBL \& MGZL (CR) 1.Complete disappearance of all detectable clinical evidence of disease. 2.Bone marrow: No evidence of FDG- avid disease in marrow. CTCL (CR) 1. 100% clearance of skin lesions. 2. all lymph nodes ≤1.5 cm, N3 classification and ≤ 1.5 cm in their long axis and \> 1 cm in their short axis at baseline, must be ≤ 1 cm in their short axis or biopsy negative for lymphoma. 3. organs should not be enlarged on examination or imaging 4. absence of blood involvement

    Time frame: From first dose to the date of relapse or death due to any cause, whichever occurs first. (about 48 months)

  4. Progression Free Survival (PFS)

    PFS is defined as the time from the date of first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death due to any cause, whichever comes first. Participants who are progression-free and alive or have unknown status will be censored at the last tumor assessment. Participants who did not have any onstudy tumor assessments and did not die will be censored on the date of first treatment. For participants who received subsequent therapy prior to documented progression, it will be censored on the last tumor assessment date prior to or on subsequent therapy.

    Time frame: From first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death due to any cause, whichever comes first. (about 48 months)

  5. Overall Survival (OS)

    OS is defined as the time from the date of first dose of study drug until the date of death (any reason). If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant was last known to be alive.

    Time frame: From the first patient first visit to 8 months after the last patient first visit (about 48 months)

07

Results

Posted Mar 7, 2023

Participant flow

Participant flow — Overall Study
MilestoneDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Started4233291030
Phase 1 dlt evaluable participants21300
Completed phase 1 dlt evaluation21300
Completed00000
Not completed4233291030
Withdrew: Disease progression29191358
Withdrew: Study drug toxicity46703
Withdrew: Ae unrelated to study drug31102
Withdrew: Request to discontinue10301
Withdrew: Participant withdrew consent30100
Withdrew: Maximum clinical benefit171313
Withdrew: Other reasons10223
Withdrew: Poor/non-compliance00100

Outcome measures

PrimarySafety Analysis - Number of Participants With Dose Limiting Toxicities (DLT) in the DLT Evaluation Phase

DLTs are defined as any study drug-related toxicity (brentuximab vedotin or nivolumab) that requires either a dose reduction or delay of more than 7 days of either study drug in Cycle 2 or delays the Cycle 3 Day 1 administration of combined treatment by more than 7 days.

Time frame:
From first dose of treatment to 6 weeks after first dose
Reported as:
Count of participants · Participants
Safety Analysis - Number of Participants With Dose Limiting Toxicities (DLT) in the DLT Evaluation Phase
ParticipantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Safety Analysis - Number of Participants With Dose Limiting Toxicities (DLT) in the DLT Evaluation Phase000——
PrimarySafety Analysis - Number of Participant Deaths

Number of participant Deaths

Time frame:
CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Reported as:
Count of participants · Participants
Safety Analysis - Number of Participant Deaths
ParticipantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Safety Analysis - Number of Participant Deaths2422335
PrimarySafety Analysis - Number of Participants With Adverse Advents

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.

Time frame:
CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Reported as:
Count of participants · Participants
Safety Analysis - Number of Participants With Adverse Advents
ParticipantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Safety Analysis - Number of Participants With Adverse Advents4233291030
PrimarySafety Analysis - Number of Participants With Serious Adverse Events

A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * results in death * is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * requires inpatient hospitalization or causes prolongation of existing hospitalization. * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event

Time frame:
CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Reported as:
Count of participants · Participants
Safety Analysis - Number of Participants With Serious Adverse Events
ParticipantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Safety Analysis - Number of Participants With Serious Adverse Events221914410
PrimarySafety Analysis - Number of Participants With Adverse Events Leading to Discontinuation

Number of participants with adverse events leading to discontinuation

Time frame:
CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Reported as:
Count of participants · Participants
Safety Analysis - Number of Participants With Adverse Events Leading to Discontinuation
ParticipantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Safety Analysis - Number of Participants With Adverse Events Leading to Discontinuation1110628
PrimarySafety Analysis - Number of Participants With Adverse Events Leading to Dose Delay or Reduction

Number of participants with adverse events leading to dose delay or reduction

Time frame:
CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Reported as:
Count of participants · Participants
Safety Analysis - Number of Participants With Adverse Events Leading to Dose Delay or Reduction
ParticipantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Safety Analysis - Number of Participants With Adverse Events Leading to Dose Delay or Reduction161514317
PrimarySafety Analysis - Number of Participants With Drug Related Adverse Events

Number of participants with Drug Related Adverse Events

Time frame:
CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Reported as:
Count of participants · Participants
Safety Analysis - Number of Participants With Drug Related Adverse Events
ParticipantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Safety Analysis - Number of Participants With Drug Related Adverse Events352725925
PrimarySafety Analysis - Percentage of Participants With Thyroid Test Abnormalities

Percentage of participants with specific thyroid test abnormalities

Time frame:
CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Reported as:
Number · Percentage of Participants
Safety Analysis - Percentage of Participants With Thyroid Test Abnormalities
Percentage of ParticipantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
TSH > ULN34.629.618.211.124.0
TSH > ULN w/ TSH ≤ ULN at baseline26.922.218.208.0
TSH > ULN w/at least 1 FT3/FT4 value < LLN11.511.113.604.0
TSH > ULN w/all other FT3/FT4 values ≥ LLN15.411.1011.18.0
TSH > ULN with FT3/FT4 testing missing7.77.44.5012.0
TSH < LLN7.77.44.511.124.0
TSH < LLN w/TSH ≥ LLN at baseline7.704.5020.0
TSH < LLN w/at least 1 FT3/FT4 value > ULN03.74.5020.0
TSH < LLN w/ all other FT3/FT4 values ≤ ULN03.7011.10
TSH < LLN w/ FT3/FT4 test missing7.70004.0
PrimarySafety Analysis - Percentage of Participants With Liver Test Abnormalities

Percentage of participants with specific Liver test abnormalities

Time frame:
CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Reported as:
Number · Percentage of Participants
Safety Analysis - Percentage of Participants With Liver Test Abnormalities
Percentage of ParticipantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
ALT or AST > 3 x ULN4.86.113.820.024.0
ALT or AST > 5 x ULN2.406.910.010.0
ALT or AST > 10 x ULN00010.06.7
ALT or AST > 20 x ULN00010.06.7
Total Bilirubin > 2 x ULN06.13.420.03.3
ALT or AST elevation > 3 x ULN w/Bilirubin > 2 x ULN within 1 day03.03.410.03.3
ALT or AST elevation > 3 x ULN w/Bilirubin 2 x ULN within 30 days03.03.410.03.3
PrimaryObjective Response Rate (ORR)

The percentage of participants with a best overall response (BOR) of CR or PR. DLBCL, PTCL, PMBL \& MGZL complete and partial response are outlined in the Lugano Classification 2014 and Lymphoma Response to Immunomodulatory therapy Criteria. CTCL complete and partial response are defined in The consensus Global Response Score assessment.

Time frame:
CTCL: 20 Months, PTCL: 26.5 Months, DLBCL: 26 Months, MGZL: 30 Months and PMBL 25.5 Months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Objective Response Rate (ORR)28.6 (19.4 to 39.4)45.5 (33.3 to 58.0)41.4 (28.8 to 55.0)70.0 (44.8 to 88.4)73.3 (60.3 to 83.8)
SecondaryDuration of Response (DOR)

DOR will be calculated from the date of initial documentation of a response (CR, or PR) to the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death due to any cause, whichever occurs first. DLBCL, PTCL, PMBL \& MGZL complete and partial response are outlined in the Lugano Classification 2014 and Lymphoma Response to Immunomodulatory therapy Criteria. CTCL complete and partial response are defined in The consensus Global Response Score assessment.

Time frame:
From the first patient first visit to 8 months after the last patient first visit (up to 48 months)
Reported as:
Median · Months
Duration of Response (DOR)
MonthsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Duration of Response (DOR)3.55 (1.18 to 36.53)4.60 (2.76 to 12.75)26.97 (2.79 to NA)20.76 (1.22 to NA)NA (23.33 to NA)
SecondaryComplete Response Rate (CRR)

The CRR is defined as the percentage of participants with a BOR (Best overall response) of CR divided by the number of treated participants. DLBCL, PTCL, PMBL \& MGZL (CR) 1.Complete disappearance of all detectable clinical evidence of disease. 2.Bone marrow: No evidence of FDG- avid disease in marrow. CTCL (CR) 1. 100% clearance of skin lesions. 2. all lymph nodes ≤1.5 cm, N3 classification and ≤ 1.5 cm in their long axis and \> 1 cm in their short axis at baseline, must be ≤ 1 cm in their short axis or biopsy negative for lymphoma. 3. organs should not be enlarged on examination or imaging 4. absence of blood involvement

Time frame:
From first dose to the date of initial objectively documented progression or the date of subsequent therapy, whichever occurs first (up to 48 months)
Reported as:
Number · Percentage of Participants
Complete Response Rate (CRR)
Percentage of ParticipantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Complete Response Rate (CRR)7.133.33.450.040.0
SecondaryDuration of Complete Response

The duration of CR will only be evaluated in participants with BOR of CR and is defined as the time from first documentation of CR to the date of relapse or death due to any cause, whichever occurs first. DLBCL, PTCL, PMBL \& MGZL (CR) 1.Complete disappearance of all detectable clinical evidence of disease. 2.Bone marrow: No evidence of FDG- avid disease in marrow. CTCL (CR) 1. 100% clearance of skin lesions. 2. all lymph nodes ≤1.5 cm, N3 classification and ≤ 1.5 cm in their long axis and \> 1 cm in their short axis at baseline, must be ≤ 1 cm in their short axis or biopsy negative for lymphoma. 3. organs should not be enlarged on examination or imaging 4. absence of blood involvement

Time frame:
From first dose to the date of relapse or death due to any cause, whichever occurs first. (about 48 months)
Reported as:
Median · Months
Duration of Complete Response
MonthsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Duration of Complete Response36.53 (9.92 to NA)7.39 (2.17 to NA)NA (NA to NA)NA (NA to NA)NA (27.89 to NA)
SecondaryProgression Free Survival (PFS)

PFS is defined as the time from the date of first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death due to any cause, whichever comes first. Participants who are progression-free and alive or have unknown status will be censored at the last tumor assessment. Participants who did not have any onstudy tumor assessments and did not die will be censored on the date of first treatment. For participants who received subsequent therapy prior to documented progression, it will be censored on the last tumor assessment date prior to or on subsequent therapy.

Time frame:
From first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death due to any cause, whichever comes first. (about 48 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Progression Free Survival (PFS)2.60 (1.38 to 2.79)4.30 (1.58 to 5.62)15.61 (4.86 to NA)21.88 (0.07 to NA)25.95 (2.63 to NA)
SecondaryOverall Survival (OS)

OS is defined as the time from the date of first dose of study drug until the date of death (any reason). If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant was last known to be alive.

Time frame:
From the first patient first visit to 8 months after the last patient first visit (about 48 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Overall Survival (OS)13.31 (6.57 to 15.87)11.07 (5.16 to 15.31)37.16 (18.63 to NA)NA (0.07 to NA)NA (NA to NA)
Post-hocSafety Analysis - Number of Participant Deaths - Extended Collection

Number of participant Deaths This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 30-March-2022)

Time frame:
from first date of treatment to final database lock. Approximately 6 years and 7 months.
Reported as:
Count of participants · Participants
Safety Analysis - Number of Participant Deaths - Extended Collection
ParticipantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Safety Analysis - Number of Participant Deaths - Extended Collection30261448
Post-hocSafety Analysis - Number of Participants With Adverse Events - Extended Collection

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 30-March-2022)

Time frame:
From first patient first treatment to first to 100 days post last treatment. Approximately 6 years and 4 months.
Reported as:
Count of participants · Participants
Safety Analysis - Number of Participants With Adverse Events - Extended Collection
ParticipantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Safety Analysis - Number of Participants With Adverse Events - Extended Collection4233291030
Post-hocSafety Analysis - Number of Participants With Serious Adverse Events - Extended Collection

A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * results in death * is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * requires inpatient hospitalization or causes prolongation of existing hospitalization. * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 30-March-2022)

Time frame:
From first patient first treatment to first to 100 days post last treatment. Approximately 6 years and 4 months.
Reported as:
Count of participants · Participants
Safety Analysis - Number of Participants With Serious Adverse Events - Extended Collection
ParticipantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Safety Analysis - Number of Participants With Serious Adverse Events - Extended Collection221914410
Post-hocSafety Analysis - Number of Participants With Adverse Events Leading to Discontinuation - Extended Collection

Number of Adverse events leading to discontinuation This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 30-March-2022)

Time frame:
From first patient first treatment to first to 100 days post last treatment. Approximately 6 years and 4 months.
Reported as:
Count of participants · Participants
Safety Analysis - Number of Participants With Adverse Events Leading to Discontinuation - Extended Collection
ParticipantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Safety Analysis - Number of Participants With Adverse Events Leading to Discontinuation - Extended Collection12111029
Post-hocSafety Analysis - Number of Participants With Drug Related Adverse Events - Extended Collection

Number of Drug Related Adverse Events This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 30-March-2022)

Time frame:
From first patient first treatment to first to 100 days post last treatment. Approximately 6 years and 4 months.
Reported as:
Count of participants · Participants
Safety Analysis - Number of Participants With Drug Related Adverse Events - Extended Collection
ParticipantsDiffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)
Safety Analysis - Number of Participants With Drug Related Adverse Events - Extended Collection352826925

Adverse events

Collected over From first patient first visit to first to final data base lock. Approximately 6 years and 7 months. All cause mortality is calculated from first treatment to final data base lock.. Approximately 6 years and 7 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DLBCL30/42 (71.4%)23/42 (54.8%)42/42 (100%)
PTCL26/33 (78.8%)25/33 (75.8%)33/33 (100%)
CTCL14/29 (48.3%)18/29 (62.1%)28/29 (96.6%)
MGZL4/10 (40%)5/10 (50%)9/10 (90%)
PMBL8/30 (26.7%)12/30 (40%)28/30 (93.3%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventDLBCLPTCLCTCLMGZLPMBL
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)13/429/334/291/102/30
PyrexiaGeneral disorders0/4210/332/291/102/30
Febrile neutropeniaBlood and lymphatic system disorders3/421/330/291/102/30
General physical health deteriorationGeneral disorders1/420/330/291/100/30
PainGeneral disorders0/420/330/291/100/30
ParaparesisNervous system disorders0/420/330/291/100/30
PneumoniaInfections and infestations4/422/331/290/101/30
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/421/332/290/100/30
Acute kidney injuryRenal and urinary disorders0/422/330/290/102/30
Small intestinal obstructionGastrointestinal disorders0/422/330/290/100/30
Most frequent other events
Showing 10 of 116
Most frequent other events
EventDLBCLPTCLCTCLMGZLPMBL
AnaemiaBlood and lymphatic system disorders5/4210/331/296/103/30
DiarrhoeaGastrointestinal disorders20/4214/3315/290/104/30
PyrexiaGeneral disorders13/4212/3314/292/107/30
FatigueGeneral disorders16/4215/338/291/102/30
NeutropeniaBlood and lymphatic system disorders8/429/330/294/1013/30
CoughRespiratory, thoracic and mediastinal disorders10/429/336/293/1013/30
NauseaGastrointestinal disorders17/4212/3310/290/105/30
Neuropathy peripheralNervous system disorders14/425/339/290/109/30
PruritusSkin and subcutaneous tissue disorders3/4210/338/291/104/30
ThrombocytopeniaBlood and lymphatic system disorders5/428/331/293/105/30

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Diffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)Total
Mean57.7 ± 13.259.1 ± 12.057.9 ± 12.3939.9 ± 15.237.3 ± 12.952.6 ± 15.6
Sex: Female, Male
Sex: Female, Male(Participants)Diffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)Total
Female20111341765
Male22221661379
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Diffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)Total
Hispanic or Latino120014
Not Hispanic or Latino1413166958
Unknown or Not Reported27181342082
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Diffuse Large B-cell Lymphoma (DLBCL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Mediastinal Grey Zone Lymphoma (MGZL)Primary Mediastinal B-cell Lymphoma (PMBL)Total
American Indian or Alaska Native000000
Asian300014
Native Hawaiian or Other Pacific Islander000000
Black or African American3251213
White363024926125
More than one race000000
Unknown or Not Reported010012
08

Study locations

27 sites
  • Local Institution - 0017
    Birmingham, Alabama 35294-3300, United States
  • University Of Miami Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Local Institution - 0012
    Tampa, Florida 33612, United States
  • Winship Cancer Institute.
    Atlanta, Georgia 30322, United States
  • University Of Chicago
    Chicago, Illinois 60637, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School Of Medicine
    Saint Louis, Missouri 63110, United States
  • Local Institution - 0003
    New York, New York 10021, United States
  • Local Institution - 0010
    New York, New York 10029, United States
  • University Of Rochester
    Rochester, New York 14642, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • Bon Secours-St Francis Hosp
    Greenville, South Carolina 29607, United States
  • University of Washington - Seattle Cancer Care Alliance
    Seattle, Washington 98109-1023, United States
  • BC Cancer Agency - Vancouver Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • Local Institution - 0011
    Toronto, Ontario M5G 2M9, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Hopital Saint Louis
    Paris, 75010, France
  • Local Institution - 0020
    Pierre Benite Cedex, 69495, France
  • Local Institution - 0018
    Bergamo, 0, Italy
  • Local Institution - 0024
    Bologna, 40126, Italy
  • Istituto Clinico Humanitas
    Rozzano (milano), 20089, Italy
  • Local Institution - 0027
    Hospitalet de Llobregat - Barcelona, 08908, Spain
  • Churchill Hospital
    Oxford, Oxfordshire OX3 7LJ, United Kingdom
  • Royal Marsden Hospital
    Sutton, Surrey SM2 5PT, United Kingdom
09

References and documents

Publications

  • Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz AJ. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. J Clin Oncol. 2019 Nov 20;37(33):3081-3089. doi: 10.1200/JCO.19.01492. Epub 2019 Aug 9. PubMed 31398081 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Jan 2020, 47 months.

Results were first posted in Mar 2023, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2015
First posted
Oct 21, 2015
StartActual
Feb 11, 2016
Primary completionActual
Jan 16, 2020
CompletionActual
Feb 7, 2022
Results first posted
Mar 7, 2023
Last update
Mar 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02581631
Collaborators
Seagen Inc.
Responsible party
Sponsor
First posted
Oct 21, 2015
Start date
Feb 11, 2016
Primary completion
Jan 16, 2020
Completion
Feb 7, 2022
Results posted
Mar 7, 2023
Last update
Mar 7, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Brentuximab Vedotin

Start the discussion